Aadi Bioscience, Inc. (AADI)

NASDAQ: AADI · IEX Real-Time Price · USD
13.69
-0.22 (-1.58%)
May 25, 2022 4:30 PM EDT - Market closed

Company Description

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.

Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Aadi Bioscience, Inc.
CountryUnited States
Founded2011
IndustryBiotechnology
SectorHealth Care
Employees54

Contact Details

Address:
9987 Carver Rd
Blue Ash, Ohio 45242-5550
United States
Phone424 473 8055
Websiteaadibio.com

Stock Details

Ticker SymbolAADI
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001422142

Key Executives

NamePosition
Dr. Neil P. Desai Ph.D.Founder, President, Chief Executive Officer, Secretary and Director
Scott M. Giacobello CPAChief Financial Officer and Treasurer
Brendan P. Delaney M.B.A.Chief Operating Officer
Mitchall G. ClarkSenior Vice President of Regulatory Affairs and Quality Assurance
Dr. Loretta M. Itri F.A.C.P., M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
May 12, 202210-QQuarterly report [Sections 13 or 15(d)]
May 12, 20228-KCurrent report
Apr 26, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2022DEF 14AOther definitive proxy statements
Apr 5, 20224Statement of changes in beneficial ownership of securities
Apr 5, 20224Statement of changes in beneficial ownership of securities
Apr 5, 20224Statement of changes in beneficial ownership of securities
Apr 5, 20224Statement of changes in beneficial ownership of securities
Mar 22, 20224Statement of changes in beneficial ownership of securities
Mar 18, 2022424B5Prospectus [Rule 424(b)(5)]
View All SEC Filings